NCT07191626Not yet recruiting
Pulsed Field Ablation of SVC and PV in Paroxysmal Atrial Fibrillation (PASPA Study)
Pulsed Field Ablation of Superior Vena Cava in Addition to Pulmonary Vein in Paroxysmal Atrial Fibrillation: A Multicenter Randomized Controlled Trial (PASPA Study)
Source: ClinicalTrials.gov · Last updated 25 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF). 650 participants will be followed for 12 months. The main goal is to see if adding SVCI reduces arrhythmia recurrence without increasing complications such as phrenic nerve injury or sinus node dysfunction.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 650 (estimated)
- First submitted
- 8 Sept 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- Changhai Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07191626
What you commit to
- Study type: Interventional
- Planned participants: 650
- From 1 Nov 2025 to the primary completion date, 1 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Absolute contraindication to anticoagulation therapy
- Stroke or myocardial infarction within 1 month prior to enrollment
- Previous atrial fibrillation ablation procedure
Other
- Intracardiac thrombus (left atrium or left atrial appendage)
- Left atrial anterior-posterior diameter \> 60 mm
- Uncontrolled hyperthyroidism
- Pregnancy or planning pregnancy
- Life expectancy less than 1 year
- Known or suspected AF triggers primarily originating from the SVC (based on pre-procedure mapping, if available)
- Inability or unwillingness to participate in the study or comply with follow-up requirements
Who the study is looking for
- Documented paroxysmal AF (episodes self-terminating within 7 days), evidenced by ECG, Holter, or event monitor
- Age between 18 and 80 years
- Willing and able to provide written informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital). No. 168, Changhai Road, Yangpu District, Shanghai, China. Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.